Hillenbrand v. Wellmark of South Dakota, Inc.

262 F. Supp. 3d 904
CourtDistrict Court, D. South Dakota
DecidedJune 29, 2017
Docket5:16-CV-05007-KES
StatusPublished
Cited by1 cases

This text of 262 F. Supp. 3d 904 (Hillenbrand v. Wellmark of South Dakota, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. South Dakota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hillenbrand v. Wellmark of South Dakota, Inc., 262 F. Supp. 3d 904 (D.S.D. 2017).

Opinion

ORDER DENYING PLAINTIFFS’ MOTION FOR SUMMARY JUDG-. MENT AND GRANTING DEFENDANT’S MOTION FOR SUMMARY JUDGMENT

KAREN E. SCHREIER, UNITED STATES DISTRICT JUDGE

Plaintiffs filed suit under 29 U,S;0. § 1132(a)(1)(B) claiming that defendant, Wellmark of South Dakota, Inc., wrongfully denied benéfíts and improperly handled claims under a group health plan operated by Wellmark and governed by the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. .§§ 1001-1461 (2012). Docket 33. Currently pending are cross-motions for summary judgment. Dockets 42 and 50. For the reasons that follow, the court denies plaintiffs’ motion for summary judgment and grants Well-mark’s motion for summary judgment.

FACTUAL BACKGROUND1

Plaintiff Gretchen Hillenbrand is an enrolled member of a Blue Select, BlueRX Preferred Plan (“the Plan”) operated by Wellmark. Dpcket 51 ¶ 1. .. Plaintiffs John Arlt, M.A., and T.A. are also covered, under the Plan. Id. ¶2. Coverage for the Plan is provided-to plaintiffs by the employer group Dakota Partnership DBA Triple Seven Ranch. Id. ¶ 4.

Plaintiffs have a number of health conditions and diagnoses that -require treatment. Gretchen suffers from Lyme disease and three different autoimmune diseases: hypothyroidism, ulcerative colitis, and po-lychondritis. Id. ¶¶ 7-8. John suffers from Lyme disease and reactive arthritis. Id. ¶9. John has also been diagnosed with Reiter’s Syndrome. AR at 2365-2367. Both M.A. and T.A. have been diagnosed-with Lyme disease. Docket 61 ¶ 10.

' To treat the plaintiffs’ health conditions and diagnoses, plaintiffs'obtain treatment from various providers.2 See SAR at 1-42, One of these providers is Dr. Elliott Black-man, who provides plaintiffs with osteopathic manipulative treatments.3 Docket 51 ¶ 11. Another of plaintiffs’ providers is Dr. Suruchi Chandra from Whole Family Wellness/Whole Child Wellness. Id. ¶ 12. Plaintiffs ' are also treated by Dr. Wayne Anderson, a licensed naturopathic physician,4 and Dr. Eric Gordon of Gordon Med[908]*908ical Associates. Id. ¶ 13. In the course of their treatment of plaintiffs, Drs. Anderson and Gordon occasionally ordered that lab tests be conducted and use Ingex, Inc. to process the lab tests. SAR at 1, 4, 7, 21, 22, 23.

The benefits covered under the Plan are listed in the Blue Select, BlueRx Preferred Coverage Manual (“Coverage Manual”).5 AR at 89-181 (copy of Coverage Manual). The Coverage Manual also lists all of the possible restrictions on coverage under the Plan. See id. One such restriction is that all treatments must be medically necessary in order for a claim to be awarded. AR at 123 (“A key general condition in order for you to receive benefits is that the service, supply, device, or drug must be medically necessary.”). As explained in the Coverage Manual,

A medically necessary health care service is one that a provider, exercising prudent clinical judgment, provides to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and is:
• Provided in accordance with generally accepted standards of medical practice. Generally accepted standards of medical practice are based on:
- Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community;
- Physician Specialty Society recommendations and the views of physicians practicing in the relevant clinical area; and
- Any other relevant factors.
• Clinically appropriate in terms of type, frequency, extent, site and du~ ration, and considered effective for the patient’s illness, injury or disease.
• Not provided primarily for the convenience of the patient, physician, or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the illness, injury or disease.
An alternative service, supply, device, or drug may meet the criteria of medical necessity for a specific condition. If alternatives are substantially equal in clinical effectiveness and use similar therapeutic agents or regimens, [Wellmark] reservefe] the right to approve the least costly alternative.

Id. It is within Wellmark’s discretion to determine if a service is medically necessary. Id. If Wellmark concludes that a service is not medically necessary, the plan member is responsible for the cost of the service. Id.

Another restriction detailed in the Coverage Manual is that Wellmark may deny benefits if Wellmark determines that the medical service or treatment is investiga-tional or experimental. AR at’ 124. “A treatment is considered investigational or experimental when it has progressed to limited human application but has not achieved recognition as being proven effective in clinical medicine.” Id. If Wellmark determines that a service or treatment is experimental or investigational, the plan member is responsible for the costs of the service. Id.

[909]*909To determine whether a claim is medically necessary, investigational or experimental, or not coverable for some other reason, see AR at 123-26 (general conditions of- coverage, limitations, and exclusions) Wellmark often must review medical documentation. For plan members who use participating providers,6 all medical documents relevant to the plan member’s claims are submitted directly to Wellmark by the provider. AR at 155. But, when plan members use nonparticipating providers,7 the plan member -is responsible for filing a claim to seek reimbursement from Well-mark. AR at 140-41; see also AR at 155-157 (describing the claims process). After a claim is submitted — regardless of whether the provider or the plan member submits the claim — the plan member receives an explanation of benefits form that details the amount the provider charged for the medical service, how Wellmark applied benefits to the claim, what amount of the claim Wellmark will pay, and what amount of the claim the plan member must pay. AR at 156. If a submitted claim is rejected in whole or in part, a plan member can initiate an internal appeal of the determination on that claim. AR at 157.

Under the Coverage Manual, after receiving notification of an adverse benefit decision, a plan member or their authorized representative has 180 days to initiate an internal appeal. AR at 165. When requesting an internal appeal, a claimant “must submit all relevant information ... including the reason for your appeal. This includes written comments, documents, or other information in support of your appeal.” Id. Wellmark’s review of the internal appeal considers “all information regarding the adverse benefit determination whether or not the information was presented or available at the initial determination.” AR at 166.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
262 F. Supp. 3d 904, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hillenbrand-v-wellmark-of-south-dakota-inc-sdd-2017.